Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 3;51(49):12246-9.
doi: 10.1002/anie.201204910. Epub 2012 Sep 11.

Discovery of small-molecule inhibitors of the TLR1/TLR2 complex

Affiliations

Discovery of small-molecule inhibitors of the TLR1/TLR2 complex

Kui Cheng et al. Angew Chem Int Ed Engl. .

Abstract

The protein complex of toll-like receptor 1 and 2 (TLR1/2) is an important regulator of innate immunity, and therefore provides an attractive target for the treatment of various immune disordres. Here we report a novel compound (CU-CPT22) that can compete with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with high inhibitory activity and specificity. Repression of downstream signaling from TNF-α and IL-1β has also been observed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
a) Dose-dependent inhibition of NO production in RAW 264.7 macrophage cells by CU-CPT22 and the negative control compound 6. b) Binding site prediction of CU-CPT22 (show in the stick representation) to TLR1/2 performed by Glide 5.6 program[23]. The six-membered carbon chain fits well into the hydrophobic channel of hTLR1, having key hydrophobic interactions with Val311, Phe312, Pro315 and Val339.
Figure 2
Figure 2
Fluorescence anisotropy titration: a) titration of the TLR1/2 protein into the rhodamine-labeled Pam3CSK4 results in significant increase of fluoresence anistropy. Addition of CU-CPT22 competes with Pam3CSK4, resulting in lower fluoresence anistropy, demonstrating competitive binding between CU-CPT22 and Pam3CSK4 for TLR1/2. Data were fitted using a one-site competition model (R2 > 0.98). b) Normalized binding of CU-CPT22 compared with the negative control, compound 6.
Figure 3
Figure 3
Specificity test for CU-CPT22 (0.5 µM) with with TLR-specific agonists used to selectively activate the respective TLRs: (1) TLR3: 15 µg/mL Poly (I:C), (2) TLR4: 10 ng/mL LPS, (3) TLR1/2: 200 ng/mL Pam3CSK4, (4) TLR2/6: 10 ng/mL FSL-1, and (5) TLR7: 100 nM R848 were used to selectively activate respective TLRs.
Figure 4
Figure 4
Downstream signaling inhibition. a) ELISA assay results showed that CU-CPT22 inhibits the TNF-α and b) IL-1β production activated by 300 ng/ml Pam3CSK4 in the RAW 264.7 cells.
Scheme 1
Scheme 1
Representative synthesis for CU-CPT22: a) phosphate-citrate buffer (pH 5), 0.2 M Na2HPO4: 0.1 M citrate = 1:1; b) horseradish peroxidase enzyme catalyst; c) four aliquots of 3% H2O2, 42% overall yield.

Similar articles

Cited by

References

    1. Lee CC, Avalos AM, Ploegh HL. Nat. Rev. Immunol. 2012;12:168–179. - PMC - PubMed
    1. Hennessy EJ, Parker AE, O’Neill LAJ. Nat. Rev. Drug Discov. 2010;9:293–307. - PubMed
    1. Zaka DE, Schmitza F, Golda ES, Diercksa AH, Peschona JJ, Valvoa JS, Niemistöb A, Podolskya I, Fallena SG, Suena R, Stolyara T, Johnsona CD, Kennedya KA, Hamiltonc MK, Siggsd OM, Beutlerd B, Aderem A. Proc. Natl. Acad. Sci. USA. 2011;108:11536–11541. - PMC - PubMed
    1. Kawai T, Akira S. Nat. Immunol. 2010;11:373–384. - PubMed
    1. Imler JL, Hoffmann J. Nat. Immunol. 2003;4:105–106. - PubMed

Publication types

MeSH terms

LinkOut - more resources